Arrowhead Pharmaceuticals, Inc. (ARWR)

Market Cap	3.13B
Revenue (ttm)	35.47M
Net Income (ttm)	-470.79M
Shares Out	124.20M
EPS (ttm)	-4.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	789,470
Open	25.91
Previous Close	26.05
Day's Range	24.90 - 25.91
52-Week Range	20.67 - 39.83
Beta	0.94
Analysts	Buy
Price Target	48.00 (+90.33%)
Earnings Date	Aug 5, 2024

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 1993
• Employees: 525
• Stock Exchange: NASDAQ
• Ticker Symbol: ARWR

Financial Performance

In 2023, ARWR's revenue was $240.74 million, a decrease of -1.03% compared to the previous year's $243.23 million. Losses were -$205.28 million, 16.6% more than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is $48.0, which is an increase of 90.33% from the latest price.

Price Target

$48.0

(90.33% upside)

Analyst Consensus: Buy